Next Article in Journal
Gluteal Artery Injuries Including Pseudoaneurysm Associated with Powered Bone Marrow Biopsies
Previous Article in Journal
Hodgkin’s Lymphoma in a Man with Dilated Cardiomyopathy and Paraneoplastic Ataxia: A Therapeutical Challenge
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Managing Acute Promyelocytic Leukemia in Patients Belonging to the Jehovah’s Witness Congregation

by
Anand P. Jillella
1,
Martha L. Arellano
1,
Leonard T. Heffner
1,
Manila Gaddh
1,
Amelia A. Langston
1,
Hanna J. Khoury
1,
Abhishek Mangoankar
2 and
Vamsi K. Kota
1,*
1
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
2
Department of Medicine, Georgia Regents University, Augusta, GA 30322, USA
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2017, 9(3), 7083; https://doi.org/10.4081/hr.2017.7083
Submission received: 23 February 2017 / Revised: 7 June 2017 / Accepted: 11 June 2017 / Published: 26 September 2017

Abstract

Acute promyelocytic leukemia (APL) is a hyper-acute leukemia and presents with cytopenias and disseminated intravascular coagulation. Jehovah’s Witnesses with APL offer a unique challenge during induction by refusing transfusion and pose a difficult challenge in this curable disease. Our focus over the last 8 years has been decreasing early deaths in APL in both academic and community centers. As a result we have extensive experience in APL induction with a proven improvement in early deaths. Three patients with APL belonging to the Jehovah’s Witness congregation were treated in our practice and published literature in treating Witnesses with APL was reviewed. It is highly imperative to prevent induction mortality in this patient population. The goal of treatment among the Witnesses is to prevent death during induction and subsequently cure them. We discuss the management and proactive measures to prevent induction mortality in this most curable blood cancer.
Keywords: acute promyelocytic leukemia; Jehovah Witness; early deaths acute promyelocytic leukemia; Jehovah Witness; early deaths

Share and Cite

MDPI and ACS Style

Jillella, A.P.; Arellano, M.L.; Heffner, L.T.; Gaddh, M.; Langston, A.A.; Khoury, H.J.; Mangoankar, A.; Kota, V.K. Managing Acute Promyelocytic Leukemia in Patients Belonging to the Jehovah’s Witness Congregation. Hematol. Rep. 2017, 9, 7083. https://doi.org/10.4081/hr.2017.7083

AMA Style

Jillella AP, Arellano ML, Heffner LT, Gaddh M, Langston AA, Khoury HJ, Mangoankar A, Kota VK. Managing Acute Promyelocytic Leukemia in Patients Belonging to the Jehovah’s Witness Congregation. Hematology Reports. 2017; 9(3):7083. https://doi.org/10.4081/hr.2017.7083

Chicago/Turabian Style

Jillella, Anand P., Martha L. Arellano, Leonard T. Heffner, Manila Gaddh, Amelia A. Langston, Hanna J. Khoury, Abhishek Mangoankar, and Vamsi K. Kota. 2017. "Managing Acute Promyelocytic Leukemia in Patients Belonging to the Jehovah’s Witness Congregation" Hematology Reports 9, no. 3: 7083. https://doi.org/10.4081/hr.2017.7083

Article Metrics

Back to TopTop